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Abstract
The presence of cytosolic double-stranded DNA molecules can trigger multiple innate immune signalling pathways
which converge on the activation of an ER-resident innate immune adaptor named “STimulator of INterferon Genes
(STING)”. STING has been found to mediate type I interferon response downstream of cyclic dinucleotides and a
number of DNA and RNA inducing signalling pathway. In addition to its physiological function, a rapidly increasing
body of literature highlights the role for STING in human disease where variants of the STING proteins, as well as
dysregulated STING signalling, have been implicated in a number of inflammatory diseases. This review will
summarise the recent structural and functional findings of STING, and discuss how STING research has promoted
the development of novel therapeutic approaches and experimental tools to improve treatment of tumour and
autoimmune diseases.
Keywords: Stimulator of Interferon Genes (STING), Double-stranded DNA sensor, Cyclic dinucleotide, cGAS
Background
Cellular stresses or infections lead to the release of DNA
molecules into the cytoplasm which may threaten the
stability of the host genome [1]. The intracellular ap-
pearance of naked DNA molecules triggers a double-
stranded (ds)DNA sensing mechanism which conse-
quently induces innate immune responses including the
production and release of type I interferons (IFN-I). This
response is central to the resolution of DNA-induced
cellular stress [2–4] and prevents the emergence of auto-
immunity [4, 5]. A recently described protein named
STING (Stimulator of Interferon Genes, also known as
TMEM173, ERIS, MITA and MPYS) is a critical regula-
tor of these innate immune responses [6–9].
STING is an endoplasmic reticulum (ER)-resident
transmembrane protein and was first recognised as part
of the ER translocon system [6, 10]. Suppression of com-
ponents of the translocon-associated protein (TRAP)
complex such as TRAP-β and Sec61 β have been found
to impair DNA-induced type I interferon (IFN-I) signals
downstream of STING [11]. The TRAP complex has
been shown to be involved in two of the ER’s major re-
sponses: protein N-glycosylation [12] and endoplasmic
reticulum-associated degradation (ERAD) [13]. Although
the functional relevance of STING in the ER translocon
system has not yet been fully elucidated, it has been pro-
posed that STING can interact with TRAP component
Ssr2/TRAPβ to enable its migration from the ER to peri-
nuclear membranes, a process key to IFN-β promoter
activation [6, 14].
Recent reports have demonstrated that cytoplasmic
DNA released by microbes and viruses can trigger
dsDNA-sensing pathways which activate STING [6, 15–
17]. STING then signals to the TANK binding kinase 1
(TBK1) / interferon regulatory factor-3 (IRF3) axis to
upregulate type I interferon production [11, 18]. As an
IKK (IκB kinase) –related kinase, TBK1 can also interact
with IκB kinases to induce phosphorylation and thus
degradation of IκB, thereby liberating NF-κB (nuclear
factor kappa B) subunits allowing their nuclear trans-
location resulting in upregulation of type I interferon
and other pro-inflammatory cytokines such as IL-6
(interleukin-6), CXCL10 (C-X-C motif chemokine 10),
CCL5 (C-C motif chemokine ligand 5) and CCL2 [19].
Table 1 summarises the pathogens that have been shown
to activate STING [6, 20–37]. Of note, STING knockout
mice generated by Ishikawa and Barber were highly sus-
ceptible to infection by the single stranded RNA viruses
vesicular stomatitis virus (VSV) and Sendai virus [6],
suggesting STING activation pathways may overlap with
RNA sensing mechanisms or reverse transcription of
viral RNA [6, 24, 38].
* Correspondence: e.kiss-toth@sheffield.ac.uk
Department of Infection; Immunity and Cardiovascular Disease, University of
Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Li et al. Journal of Inflammation  (2017) 14:11 
DOI 10.1186/s12950-017-0159-2
Whilst the STING-mediated dsDNA-sensing mechan-
ism is critical for successful cellular protection against
infections and disease progression, dysregulated STING
activity leads to the excessive production of inflamma-
tory mediators with potentially detrimental effects on
surrounding cells and tissues. Recent studies revealed
some important functions for STING in autoinflamma-
tory diseases [39–41], cancer [41–44] and lipid regula-
tions [45, 46], highlighting the importance of this
protein in health and disease. Here we review the recent
insights into STING function in human pathologies and
discuss the potential of STING-targeted therapies which
are of considerable scientific and clinical interest.
Main text
STING mediated signalling
Canonical STING activators
Whilst STING acts as an adaptor protein in the dsDNA
sensing pathway, it is not activated directly by DNA
molecules. Instead, STING responds to DNA sensing
proteins and molecules known as cyclic dinucleotides
(CDNs) [35, 47–49] (Figure 1). CDNs are derived from
infectious agents exogenously, or are produced by the
mammalian dsDNA sensor cGAS (cyclic guanosine
monophosphate – adenosine monophosphate synthase;
cyclic GMP-AMP synthase). The canonical CDNs, or
microbial secretory CDNs, are molecules made of 3′-5′
phosphodiester bonds joining two adenosines (A) – cyc-
lic di-AMP [35, 50], two guanosines (G) – cyclic di-
GMP [47] or one of each – cyclic GMP-AMP [37]. One
of the STING-activating universally expressed DNA sen-
sors, cGAS, is capable of catalysing a unique form of
CDN endogenously upon DNA recognition [51]. This
molecule is comprised of one 3′-5′ phosphodiester bond
and a non-canonical 2′-5′ linkage between adenosine
and guanosine, and is thus named 2′-3′ cGAMP to dis-
tinguish from the secretory cyclic dinucleotide cGAMP
(3′-3′ cGAMP) which contains two 3′-5′ bonds [37].
Previous literature [52–54] has suggested that 2′-3′
cGAMP is ten- to a thousand-fold more potent than 3′-
3′ cGAMP in activating STING. A number of studies re-
ported that the change of phosphodiester linkage in 2′-
3′ cGAMP results in a higher binding affinity to STING
and thus leads to an augmented type I interferon
Table 1 STING is activated by a range of pathogens
Name Type of Pathogen Mechanism of STING activation References
Adenovirus Non-enveloped linear
dsDNA virus
dsDNA activates cGAS-STING pathway (cytoplasmic) [20]
Kaposi’s sarcoma-associated
herpesvirus
Enveloped dsDNA virus dsDNA activates cGAS-STING pathway (cytoplasmic) and IFI16-STING pathway
(nuclear)
[21]
Herpes simplex virus Enveloped dsDNA virus dsDNA activates cGAS-STING pathway (cytoplasmic) and IFI16-STING pathway
(nuclear)
[22, 23]
Epstein-Barr virus dsDNA virus dsDNA activates IFI16-STING pathway (nuclear) [24]
Human cytomegalovirus dsDNA virus dsDNA activates cGAS-STING pathway (cytoplasmic), DAI-STING (cytoplasmic),
and IFI16-STING pathway (nuclear)
[25–27]
Sendai virus Negative strand ssRNA
virus
Possibly via RIG-I –dependent RNA detection which may in turn induce STING [6]
Vesicular stomatitis virus Negative strand ssRNA
virus
Unknown [6]
Human immunodeficiency
virus
Negative strand ssRNA
virus
dsDNA reverse transcribed from viral RNA induces cGAS-STING pathway [28]
Influenza A virus Negative strand ssRNA
virus
Possibly via membrane fusion or unknown mechanism independent of DNA
recognition
[29]
Mycobacteria tuberculosis Bacteria producing c-di-
GMP
c-di-GMP [30, 31]
Streptococcus pneumoniae Bacteria dsDNA Bacterial dsDNA [32]
Streptococcus pyrogenes Bacteria dsDNA Bacterial dsDNA [33]
Staphylococcus aureus Bacteria producing c-di-
AMP
c-di-AMP [34]
Listeria monocytogenes Bacteria producing c-di-
AMP
c-di-AMP [35]
Vibrio cholera Bacteria producing 3′-3′
cGAMP
3′-3′ cGAMP [36, 37]
Abbreviations: dsDNA double-stranded DNA, ssRNA single-stranded RNA
The type I interferon signal adaptor protein STING is responsible for mediating double-stranded DNA sensing responses and the detection of bacterial cyclic dinu-
cleotides c-di-AMP, c-di-GMP, and 3′-3′ cGAMP. Many DNA viruses, RNA viruses and bacteria have been implicated in the activation of STING
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response [55, 56]. It is also possible that hydrophilic
secretory cyclic dinucleotides are excluded by the select-
ively permeable plasma membrane [57], and thus cannot
be recognised by STING.
Alternative STING activators
In addition to being activated by cyclic dinucleotides,
STING also mediates antiviral responses downstream of
DNA sensors including DNA-dependent activator of
IFN-regulatory factor (DAI) [17], IFNγ-inducible protein
16 (IFI16) [15], DEAD-Box Helicase 41 (DDX41) [16],
and components of the RNA-sensing pathways [23, 38]
(Figure 1). The Z-form DNA sensor DAI was the first
identified activator for STING, whose expression is
highly cell-type and tissue-specific and therefore could
not fully account for the widespread IFN-I induction
during viral infection [17, 58]. Further research identi-
fied that the DNA sensor DDX41 could interact with
bacterial cyclic dinucleotides, in addition to DNA mole-
cules [16], prior to activating STING signalling [59].
Another interferon-inducible DNA sensor IFI61 is a
pyrin-containing protein which also induces STING acti-
vation downstream of DNA detection. IFI16, as well as
its mouse orthologue p204, is a universally expressed
DNA sensor, which forms multimers prior to STING ac-
tivation in response to HSV viral infections [15, 60]. Evi-
dence shows that IFI16 is responsible for detecting
foreign DNA both in the cytoplasm and in the nucleus
and therefore it is capable of combating nuclear-
replicating viruses such as Kaposi’s Sarcoma associated
herpesvirus [61, 62] and human cytomegalovirus
(HCMV) [27, 63], implying an ability to discriminate
between “self” and “non-self” DNA molecules. A recent
report by Diner and colleagues showed dynamic regula-
tion of IFI16 oligomers at different cellular compart-
ments in response to altered viral infections [64].
Throughout HCMV infection, IFI16 oligomers are
densely gathered nuclear “punctate” structures, whereas
in Herpes simplex virus-1 (HSV-1) infection these
“puncta” become gradually dispersed across the whole
nucleoplasm and are eventually degraded. In contrast to
previous studies, Diner et al. also found that IFI16
knockout cells do not impede TBK1 activation upon im-
mune stimulation, whereas both STING and cGAS
knockout cells will strongly suppress TBK1 activity, sug-
gesting that nuclear DNA detection mediated by IFI16 is
independent of the STING/TBK-1/IRF3 axis. Other
studies indicate that antiviral cytokine production occurs
in the absence of IFI16 via an unknown mechanism [64].
Recent reports have revealed an interesting relation-
ship between IFI16 and cGAS during DNA detection. It
was shown that HSV infection can induce both DNA
sensors in various cell types, and that cGAS is partially
nuclear, thus is able to regulate the stability of nuclear
IFI16 oligomers during detection of viral DNA [65]. This
provides a molecular mechanism by which cGAS regu-
lates nuclear DNA sensing. Further evidence also sug-
gests a DNA dose-dependent interaction between IFI16
and cGAS in keratinocytes [66]. Although this inter-
action does not affect cGAS’s ability to generate cyclic
dinucleotides, evidence indicates that IFI16 can facilitate
the detection of these ligands by STING, and the loss of
IFI16 can significantly impair downstream type I inter-
feron and pro-inflammatory signalling [66]. Therefore,
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Fig. 1 STING activation pathways. The endoplasmic reticulum (ER) adaptor STING is activated via recognition of bacteria-secreted 3′-5′ bond cyclic
dinucleotides or DNA sensor cGAS-catalyzed 2′-5′ cGAMP. Cytoplasmic DNA, released from DNA viruses or reverse transcribed from the RNA viral
genome, can induce direct interaction between STING and DNA sensors (in red) such as DDX41, IFI16, and DAI. Alternatively, RNA viruses also in-
duce the RIG-I dependent MAVS activation which alters mitochondrial dynamics and indirectly induce STING activation. Mitochondrial stress can
result in the release of mitochondrial DNA (mtDNA) which also induces DNA sensor activation (not shown) and STING-mediated signalling. RNA
polymerase III (RNA Pol III) can convert dsDNA into dsRNA which activates RIG-I/ MAVS axis which has been shown to induce STING activation
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IFI16 and cGAS are not redundant during DNA infec-
tions, but instead cooperate and regulate each other’s
activities.
RNA-induced STING activation
Interestingly, several RNA viruses such as human im-
munodeficiency virus (HIV) [28, 67], influenza A virus
[29], Sendai virus and vesicular stomatitis virus [6] have
been found to activate STING signalling, via mecha-
nisms both dependent and independent of DNA detec-
tion. Complementary DNA (cDNA) produced from
reverse transcription of negative-stranded RNA in retro-
viruses such as HIV, murine leukemia virus (MLV) and
Simian immunodeficiency virus (SIV) can induce a
cGAS-dependent DNA sensing pathway and STING ac-
tivation [28, 68] (Figure 1). However, HIV, in particular,
is capable of inhibiting transcription of immediate anti-
retroviral factors [69] and exploits the host STING
blocker NOD-like receptor NLRX1 to aid the establish-
ment of virus latency [67, 69]. It was also reported that
cationic liposomes and nucleic acid-free herpesvirus-
derived virus-like particles can directly induce STING/
TBK1 relocation regardless of DNA sensing pathways,
suggesting that the membrane fusion mechanism may
be an alternative route for enveloped DNA and RNA vi-
ruses to activate STING. Enveloped RNA virus Influenza
A virus has been shown to release haemagglutinin fusion
peptide which induces STING but not cGAS activation
[29], thus indicating another STING activation mechan-
ism independent of cyclic dinucleotide recognition. It re-
mains unclear whether the fusion particles alone are
direct STING ligands or if activity requires facilitation
by unidentified co-regulator(s).
The RNA-inducing adaptor MAVS (mitochondrial
antiviral signalling protein; also known as VISA, Cardif,
IPS-1) can also interact with and activate STING [6, 8]
(Figure 1). The mitochondria-resident adaptor MAVS is
the major molecular platform through which the RLR-
dependent RNA sensing pathway elicits the type I inter-
feron response. MAVS responds to the cytoplasmic
RNA sensors RIG-I (the retinoic acid-inducible gene I)
and MDA5 (melanoma differentiation-associated protein
5) [70], and in turn induces proinflammatory transcrip-
tion factors NF-κB (nuclear factor kappa-light-chain-en-
hancer of activated B cells), IRF1, IRF3, IRF5 and IRF7
[70–73]. Castenier and colleagues [74] found that RIG-I
induced MAVS activation can modulate mitochondrial
dynamic changes promoting signalling to STING at
MAMs, “mitochondria-associated membranes”, where
mitochondria and ER are closely associated [75]. This
adaptor interaction was found to be dependent on a
mitochondrial fusion mechanism which induces mito-
chondrial elongation towards the ER, and hence MAM
formation. Virus-induced mitochondria fragmentation
disrupts membrane association and hence abolishes
MAVS activation and secondary STING signalling [74].
Another report also suggests that RNA virus-induced re-
lease of stress-associated mitochondrial (mt)DNA acti-
vates the STING-dependent dsDNA sensing pathway
[76]. This process, which is also likely to involve mito-
chondrial stress-induced apoptosis, may provide an ef-
fective means to remove damaged cells for infection
control.
Ablasser [77] and Chiu [78] noted that the STING in-
ducer and a B-form dsDNA sensor RNA polymerase III
(Pol III) activate the RIG-I –dependent RNA sensing
pathways (Figure 1). RNA Pol III reversely transcribes
dsDNA into dsRNA molecules that are activators of
RIG-I. However, it is unclear how STING is involved in
this process.
Post activation trafficking of STING
Activation of STING induces adaptor dimerization [7] and
subsequent migration from ER membranes to punctate
membranes of the Golgi by mechanisms similar to autoph-
agy [11]. It remained difficult to identify the role of STING
in autophagy regulation as little evidence was found to link
STING with the recycling process during cell starvation.
Yet many autophagy-related proteins such as autophagy-
related gene (Atg) 9a and Vps34 are key to STING inter-
organelle trafficking [79], and that the loss of early autoph-
agy marker LC3 II can significantly impair the STING-
dependent innate response to viral and bacterial infections
[79–81]. This autophagy-like behaviour could also be re-
lated to the ER-originated pre-autophagosome formation,
where STING is located [41].
Signalling downstream of STING
The STING-dependent cellular responses are mainly
dependent on two transcription factors, IRF3 and NF-κB
(Figure 2). STING activation first induces adaptor di-
merisation [82] and TRIM56-dependent ubiquitination
to enable TBK1 docking [83]. Together, STING and
TBK1 migrate to the perinuclear membranes of the
Golgi via autophagy-like processes [6, 18, 79]. The asso-
ciation between STING-TBK1 leads to auto-
phosphorylation of TBK1 at S172, a residue known to
induce TBK1 activation [84, 85]. This further allows
TBK1 to phosphorylate STING at S358 and S366 (S357
and S365, respectively, in mouse STING). Phosphory-
lated S366, together with L374, are important for the re-
cruitment of IRF3 in close proximity to TBK1 at the C-
terminus of STING, thereby enabling TBK1 to phos-
phorylate and activate IRF3 by exposing its nuclear lo-
calisation signal [18]. Activated IRF3 then translocates
into the nucleus and promotes expression of type I inter-
ferons. Via a rapid feedback mechanism, IFN-I is re-
leased and binds to cell surface interferon receptors
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(IFNαRs), which then induces the expression of
interferon-stimulated genes (ISGs) via Tyk2/JAK1 [86–
88] and STAT1-STAT2 dimers [89, 90].
STING ligands have also been shown to activate the
canonical NF-κB pathway (Figure 2), leading to the
production of pro-inflammatory cytokines including
IL-1α, TNF-α (tumour necrosis factor-α), IL-6, and
numerous chemokines such as CXCL10 and CCL-2
[9, 19]. The mechanism of this was found to be
dependent on STING-TBK1 activation, which in turn
regulates the activation loop of IKKα/β releasing p65
to form active dimers with p50. Hence, the functional
NF-κB complex can translocate into the nucleus and
promote transcription of pro-inflammatory genes. Abe
and Barber also suggested that TRAF6 may be in-
volved upstream of TBK1, which likely facilitates NF-
kB activation [19]. However, the IFI16-dependent
STING pathway can only induce IRF3 but not NF-κB
activation, which would serve to preserve the survival
activities regardless of the antiviral response during
infection [91].
Regulatory motifs of STING activity
The sequence and topology of STING has been studied
in parallel to its function. It is known that STING is a
379 amino acid long ER transmembrane protein
encoded by the human TMEM173 gene (Accession
NP_938023, XP_291127) and homologous genes in
other mammalian species. The STING structure is
highly conserved between mammalian species, with the
N-terminal forming a putative multi membrane-
spanning region, a middle CDN-recognition domain,
and a cytoplasmic tail (Figure 3).
It is understood that the N-terminal 130 amino acids
of STING form four transmembrane helices [92, 93] that
are mainly responsible for membrane anchorage and
inter-organelle trafficking [94] (Figure 3). An additional
helix, named helix α1, was previously considered as the
fifth transmembrane domain [6, 8, 95, 96] but has more
recently been proposed to form a distinct domain with
different functions [97]. Helix α1 is formed between resi-
dues 153–177 and has been reported to play an essential
role in protein folding and dimerisation. Compromising
Fig. 2 STING activated signalling pathways. STING activation leads to translocation from ER membranes to the perinuclear vesicles where it induces the signalling
of two major pathways: the NF-κB -dependent proinflammatory response and the IRF3-dependent type I interferon response. The activation of mitochondrial
antiviral adaptor MAVS also results in the activation of STING and recruitment of TBK1, which upregulates the transcription of antiviral chemokines via STAT6
Fig. 3 The domain structure of human STING protein. Human STING is a 379 amino-acid long ER-resident protein. The N-terminal contains 5
membrane-embedded domains (dark blue) including 4 transmembrane domains and Helix α1 responsible for ligand sensing and protein dimer-
isation. The C-terminal is mainly cytoplasmic (pale blue). It contains the cyclic dinucleotide (CDN) binding domain and interaction sites for TBK1
and IRF3 at the tail. Numbers above STING sequence indicate the amino acids comprising the functional domain
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the integrity of helix α1 causes STING precipitation in
the cytoplasm and abolishes the homo-dimeric structure
due to the loss of abundant hydrophobic interactions be-
tween dimers [97]. Ouyang’s group reported that helix
α1 also supports strong hydrogen force between STING
dimers and cyclic di-GMP, suggesting its importance in
multiple STING functions [98].
In addition to helix α1, the rest of the cytoplasmic tail
also contributes to STING dimerisation [7], cyclic di-
nucleotide recognition [99], and TBK1 and IRF3 recruit-
ment [18, 100] (Figure 3). In the absence of ligands,
STING dimers show an open structure susceptible to
cyclic dinucleotides [98]. Upon recognition of cyclic di-
GMP, residues 139–344 are rearranged to expose a
docking site for TBK1 [98], enabling TBK1 to phosphor-
ylate STING at serine 358 [8]. This phosphorylation in
turn enhances TBK1-STING attachment. Tanaka’s group
found that a 39-residue fragment at the carboxyl end of
the STING protein was sufficient to activate IRF3 signal-
ling in response to DNA challenge [18], and the loss of
this tail region, encoded by exon 7, creates a dominant
negative STING isoform for TBK1-IRF3 signalling [101].
Further truncation of the STING C-terminal fragment
revealed that S366 and L374 are the key residues for
IRF3 recruitment and activation [18]. Therefore, TBK1
and IRF3 are recruited to STING in a 20 amino acid –
spanning region to facilitate their interaction by close
proximity.
Crystallisation of the STING protein has revealed that
key residue substitutions or segment deletions signifi-
cantly alter its structure, resulting in a dysfunctional
protein [6, 7, 53, 97, 98, 102]. Mutations of single or
multiple amino acids of STING have been found to in-
fluence its dimerisation capability [39, 103–105], ligand
binding capacity [39, 104–106], or the ability to be post-
translational modified by regulatory proteins [102, 107].
Some of these mutations occur naturally in humans to
cause lethal autoinflammatory diseases [39, 105, 108],
and some were generated experimentally in order to
understand the structure-function relationship of STING
[53, 96, 97, 102].
STING variants
STING variations exist between mammalian species; the
amino acid sequences of human and mouse STING are
68% identical and 81% similar [54]. Whilst this may not
lead to dramatic differences in their three-dimensional
structures, the structural differences at certain amino
acid residues may be responsible for species-specific im-
mune responses to some viral infections. For instance,
Dengue virus (DENV) can inhibit STING signalling in
human but not in mouse [107, 109]. DENV encodes for
the protease NS2B3 that cleaves human STING at a
highly-conserved putative cysteine motif (C88XXC91) to
disable the adaptor. The equivalent cleavage target in
mouse STING (mSTING) harbours a mutation that pre-
vents NS2B3 cleavage, thus mouse STING can avoid
DENV evasion. Mutant mouse embryonic fibroblasts
transfected with hSTING re-constructed with a mouse
NS2B3 cleavage site sequence blocks the type I inter-
feron response against DENV. Specifically, a substitution
of S135A in hSTING sequence results in inhibition of
NS2B3 cleavage, suggesting that protecting STING at
this residue may provide the basis for a novel anti-
Dengue treatment [107].
In humans, single nucleotide polymorphisms (SNP) of
STING were found to result in different levels of IFN-I
signalling modulation (Table 2). Substitution at R284M
can greatly stabilize the STING dimer, indicating its
strong potential to cause chronic STING-dependent
autoimmunity [103]. Substitution at R293Q can strongly
reduce the c-di-GMP –induced IFN-I signals and com-
pletely abolishes the signals induced by other 3′-5′ bond
cyclic dinucleotides [104]. Other single residue polymor-
phisms such as R232H and G230A may affect the ligand
binding pocket of STING, thereby reducing its response
to bacterial ligands [104]. In particular, a loss-of-
function triple STING mutant, R71H-G230A-R293Q
(named HAQ), abolishes almost 90% of the interferon
response to all cyclic dinucleotides [110]. The HAQ mu-
tant occurs in one-fifth of the population from a thou-
sand genome screen [104]. Homologous HAQ mutant
knock-in mice have demonstrated that a variety of im-
mune cells, including lymphocytes and Ly6Chi mono-
cytes, express significantly less STING protein compared
to the wildtype, and the mutant animals completely
failed to respond to CDN challenge [106]. This sug-
gested that the HAQ mutant may be a de facto null al-
lele of STING, thereby reducing the availability of the
STING protein to mediate a dsDNA sensing response.
The function of several STING residues has been char-
acterised using experimental point mutations (Table 2),
some of which were also found to occur naturally in
mammals. A C57BL/6 –derived, Goldenticket (Gt)
mouse strain harbouring a single I199N mutation in
STING leads to the complete abolishment of IFN-I ac-
tivity to Listeria monocytogenes infection or stimulation
of cyclic di-GMP and cyclic di-AMP [111]. The human
equivalent mutation I200N was also considered to have
the same effects, but no such spontaneous mutant has
been discovered. Only a few gain-of-function hSTING
mutants have been identified clinically [39, 105] (Table
2). Patients with these STING mutations showed early
on-set of severe systemic inflammation in blood vessels
and various organs, displaying chronic inflammatory
symptoms that are highly similar to pathologies of SLE
(systemic lupus erythematous) and AGS (Aicardi-Gou-
tières Syndrome) [39, 105]. All of these STING mutants
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have shown considerable structural resemblance to the
active conformation, presumably leading to constitutive
adaptor dimerization and signalling to type I interferon
production. Both Liu and König’s groups suggested that
inhibition of the interferon signalling adaptor JAK could
significantly dampen IFN-I over-expression as measured
in biopsy samples from these patients, indicating that
JAK inhibitors could be a promising avenue to thera-
peutically control disease progression.
As evidenced by the above studies, STING variants are
likely to be associated with increased susceptibility to
certain infections and autoimmune diseases, emphasis-
ing the value of genetic analysis of individual mutations
to reveal novel targets for developing personalised ther-
apy and immunisations.
STING regulations
As a critical coordinator of the innate immunity, STING
is tightly regulated by a variety of signalling molecules.
Except that STING is post-translationally modified to
enable dimerisation and activation, some regulators are
essential for the prevention of constitutive type I inter-
feron signalling which have been shown to cause
autoimmunity both in animal models [6, 112] and in hu-
man [39, 108]. Negative regulation of STING signalling
is necessary for the resolution of inflammatory responses
post infection (Figure 4).
Post-translational regulators
Post-translational modifications contribute to the spatio-
temporal regulation of STING signalling. STING is com-
monly modified by ubiquitination and phosphorylation.
Upon ligand binding, the E3 ubiquitin ligase TRIM56 is
recruited to initiate K-63 linked ubiquitination on
STING, a prerequisite for STING dimerisation and acti-
vation [83]. Another E3 ligase AMFR (Autocrine motility
factor receptor), together with its interacting partner
INSIG1 (insulin-induced gene 1), catalyses K-27 linked
poly-ubiquitination, which is critical for TBK1 recruit-
ment [113]. In contrast, TRIM30α-dependent K275 ubi-
quitination [112] and RNF5 (RING finger protein 5)
-dependent K150 ubiquitination [114] degrade STING
dimers and negatively regulate antiviral signalling (Figure
4). This process is likely to involve the antiviral adaptor
protein MAVS on mitochondria at the MAMs where the
closely associated ER and mitochondrial membranes
Table 2 Mammalian STING variants and mutants
Mutation Motif Functional effect/ Disease association Occurrence References
S162A ligand binding site Reduce c-di-GMP binding
Increase hSTING sensitivity to DMXAA
N/A [53]
G230A ligand binding site Impair C-terminal binding to c-di-GMP N/A [104]
G230A-R293Q ligand binding site Double mutant
Partially reduced IFN-β response to bacterial ligands
5.2% / 1000
human genome
[104]
R293Q ligand binding site Significantly reduced IFN-β response to bacterial ligands 1.5%/ 1000 human
genome
[104]
R232H ligand binding site Partially reduced IFN-β response to c-di-GMP and complete loss of
IFN response to other bacterial ligands
13.7% / 1000
human genome
[104]
R71H-G230A-
R293Q (HAQ)
Recessive
Null allele
Triple mutant
Low intrinsic IFN-β/NF-κB promoter activity
Homologous significant decrease STING expression and abolish IFN-I
response to all STING ligands
20.4% / 1000
human genome
[104, 106,
110]
V155 M Hydrophobic core,
ligand binding site
SAVI, constitutive activation Very rare [39, 108]
N154S Hydrophobic core,
ligand binding site
SAVI, constitutive activation Very rare [39]
V147 L Hydrophobic core,
ligand binding site
SAVI, constitutive activation Very rare [39]
I200N Interior STING promoter Complete abolish STING activity, equivalent to I199N mSTING
missense mutation, Goldenticket strain
N/A [111]
G160E Dimerisation domain FCL, constitutive activation Very rare [105]
S366A (loss) or
S366D (gain)
Ulk1/2 target
phosphorylation site
Both loss-of-function (S366A) & gain-of-function (S366D) mutations
block IRF3 binding
N/A [102]
Single nucleotide polymorphisms of STING have been discovered in human and mouse which are implicated in dysregulation of type I interferon signalling and
the proinflammatory innate immune response. STING mutations highlighted in green manifest as loss-of-function characteristics, mutations highlighted in red
manifest as gain-of-function characteristics, and mutation in black lacks any gain-of-function or loss-of-function characteristic of STING. Gain-of-function mutations
of V155 M, N154S and V147 L have been identified in human autoinflammatory disease called STING-associated vasculopathy with onset in infancy (SAVI), and
substitution of G160E is the major cause of another human autoimmune disease known as familiar chilblain lupus (FCL). The most predominant loss-of-function
STING mutant named HAQ is considered to compromise host innate response against infection, yet no clinical evidence is available for further discussion. Others
STING mutations are experimentally created to study type I interferon signalling pathways, but they are potentially pathological
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bring STING and MAVS in close proximity [115, 116].
Since ubiquitination is critical to STING regulation,
some viruses can secrete proteases to specifically disrupt
this process to suppress innate immune recognition, as
summarised below (Table 3).
Some STING activities are also critically dependent
on its phosphorylation. One such example is the
phosphorylation of S366 on the C-terminal domain to
provide docking sites for IRF3 prior to its phosphor-
ylation by TBK1 [6, 100, 117]. ULK1-dependent phos-
phorylation on S366 post Golgi trafficking blocks
IRF3 binding to STING and thus prevents chronic
STING activation [102] (Figure 4). ULK1 acts upon
release from its repressor AMPK (adenosine mono-
phosphate activated protein kinase) which is induced
by production of 2′-3′ cGAMP from cGAS. Interest-
ingly, both loss-of-function (S366A) and gain-of-
function (S366D) mutations can abrogate IRF3 signal-
ling [18], suggesting that either the phosphorylation
of S366 is temporally and spatially regulating IRF3
docking, or that alternative post-translational modifi-
cations are responsible for this functional regulation.
In particular, S366-dependent inhibition of IRF3 does
not impair the NF-κB pathway, indicating that these
two pathways act independently of each other, which
has likely evolved to prevent dysregulated antiviral re-
sponses from affecting survival activities [102].
STING can be negatively regulated by the NLR family
inflammasome components NLRC3 [118] and NLRX1
[67] (Figure 4). Both of these have been shown to se-
quester STING to prevent TBK1 recruitment; in particu-
lar the latter is strongly enhanced in HIV infection to
suppress STING-dependent recognition of reverse-
transcribed dsDNA [67]. Depletion of NLRX1 not only
impedes nuclear transportation of viral DNA, but also
restores the STING-mediated interferon response to stall
progression of infection. This suggests that pharmaco-
logical suppression of intrinsic STING inhibitors could
potentially support the re-establishment of STING-
mediated innate immunity against RNA viruses, and
thus may offer promising adjuvant therapy to combat
retrovirus infection. However, Guo and colleagues also
noted that such suppression must be finely controlled to
avoid excessive inflammatory responses that may lead to
autoimmunity [67].
Post-transcriptional regulation
A primate specific microRNA (miR)-576-3p has been
identified as a novel STING regulator that promotes
virus replication [119] (Figure 4). Over expression of this
microRNA promotes the spread of vesicular stomatitis
virus, whereas its inhibition protects against virus
growth. Further studies show that miR-576-3p is an
IRF3-induced gene that can target multiple genes of
Fig. 4 Negative regulation of STING-mediated response. STING-mediated signalling can be negatively regulated via multiple mechanisms, including E3
ubiquitin ligase TRIM30α- and TRIM21- mediated degradation of STING and its upstream DNA sensor DDX41, respectively. Certain phosphodiesterases
(PDEs) also specifically hydrolyse bacterial cyclic dinucleotides to prevent them being sensed by STING. Akt kinase is also capable of inhibiting cGAS
detection of cytoplasmic DNA. Activated cGAS produces 2′-3′ cGAMP to release AMPK-mediated inhibition of ULK1, which in turn blocks IRF3 recruitment
downstream of STING activation. 2′-3′ cGAMP produced by cGAS can also activate Beclin-1 which can sequester cGAS as well as induce degradation of
dsDNA. In a negative feedback loop, the product of the IRF3-dependent antiviral response, microRNA-576-3P (miR-576-3P), can prevent further STING
activation. Some viruses can encode proteases or protein inhibitors to interfere in STING signalling, while others may enhance the activity of inflammasome
complexes NLRC3 and NLRX1 to block STING/ TBK1 interaction
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interferon-stimulators, including STING, MAVS, TRAF3
and STAT6, thereby reducing their levels [119]. Since
IRF3 is a downstream signalling molecule in the STING-
TBK1 axis, upregulation of miR-576-3p serves as a nega-
tive feedback loop to prevent sustained inflammatory re-
sponse during and post infections.
Alternative mechanism of STING downregulation
A recent discovery suggests that certain phosphodiester-
ases (PDEs) may specifically degrade bacterial cyclic di-
nucleotides to halt excessive STING activation [120–
123] (Figure 4). The pathogen Mycobacterium tubercu-
losis secretes phosphodiesterases MtbPDE (Rv3586),
cnpB and CdnP to remove cytosolic CDN, thus avoiding
STING mediated detection [124–126]. Although this
may appear to undermine bacterial virulence and growth
signals that are critical to infection [124], it can also sig-
nificantly reduce early type I interferon induction. In
particular, the enzyme CdnP can degrade both bacterial-
derived and host-derived cyclic dinucleotides, critically
promoting survival of M. tuberculosis at early stages of
infection [125].
In addition to the above regulatory mechanisms, Akt
kinase (or protein kinase B, PKB) has been shown to
phosphorylate cGAS at residues S291 or S305 to stall
signalling via STING [127], while the E3 ubiquitin ligase
TRIM21 can specifically target the DNA sensor DDX41
at residues K9 and K115 for proteasome degradation
and hence prevent recognition of DNA and STING-
dependent type I interferon expression [128] (Figure 4).
The autophagy protein Beclin-1 may also terminate
STING-dependent immunity by sequestering cGAS and
promoting autophagy-dependent digestion of dsDNA
[129] (Figure 4). This is thought to prevent prolonged
DNA recognition, which could lead to autoimmunity.
STING in parasitic infection
Immune responses to malaria infection are highly strain
specific; the lack of understanding linked to these strain
specific responses makes the disease clinically difficult to
manage [130–132]. Recent studies on host-parasite
interaction have revealed distinct roles for STING-
dependent type I interferon responses during crosstalk
with other pro-inflammatory pathways. CD40 receptors
expressed on antigen-presenting cells are understood to
initiate the cellular and humoral response of the adap-
tive immunity, specifically enhancing the generation of
immunoglobulins against pathogens [133, 134]. Mice in-
fected with Plasmodium yoelii nigeriensis, infected red
blood cells, TLR ligands or parasitic DNA/RNA upregu-
late both CD40 and type I interferon expression,
whereas the loss of CD40 can reduce the level of STING
further impairing the early type I interferon response in
macrophages and dendritic cells [135]. Although CD40-
induced STING upregulation leads to reduced CD40
levels and thus downstream NF-κB signalling, type I
interferon immunity has been suggested to be highly in-
ducible in certain strains of parasitic infection [135].
Table 3 STING-mediated evasion of antiviral immunity
Pathogen Mechanism of Action References
Yellow fever virus
Dengue virus
NS4B interrupts STING activation [11]
Hepatitis C virus NS3/4A, NS4B proteases interrupt STING activation [137, 138]
Herpes simplex virus-1 Release ICP0 E3 ubiquitin ligase to degrade IFI16
Viral protein ICP27 binds to STING-TBK1 complex to prevent IRF3 signalling
[139, 140, 147]
Coronaviruses SARS and NL63 Disrupt K63-linked ubiquitin-mediated STING dimerisation [140]
Human papillomavirus E2 protein inhibits STING transcription
E7 oncogene blocks cGAS/STING signalling
[141, 142]
Adenovirus E1A oncogene blocks cGAS/STING signalling [142]
Hepatitis B virus Disrupts K63-linked ubiquitin-mediated STING dimerisation [143]
Kaposi’s sarcoma-associated herpesvirus ORF52 proteins bind to and inhibit cGAS
Targets IFI16 degradation during lytic reactivation
[62]
Epstein-Barr virus,
Murine gammaherpesvirus 68,
Rhesus monkey rhadinovirus
ORF52 proteins bind to and inhibit cGAS [144, 145]
Human immunodeficiency virus Enhance STING suppressor NLRX1
Enhance TREX1 to degrade excessive cDNA
Viral Capsids prevent innate sensing of cDNA
[67, 65, 68, 146, 148]
Human cytomegalovirus Tegument protein pUL83 disrupts IFI16 oligomerization and activation [63]
A number of DNA and RNA viruses have been found to encode and secrete STING-targeted proteases or inhibitors to prevent innate immune detection to help es-
tablish the of latent phase of infection. Viruses of the same family tend to adopt similar strategies/mechanisms to block STING activation. Some viruses also ex-
press multiple inhibitors to target both DNA sensors and STING, or release viral oncogenes in parallel to further compromise immunity, which consequently
increases their chance of survival in the host
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The establishment of malaria infection in the host is
critically dependent on early innate immune mecha-
nisms. Yu et al. suggested that depletion of plasmacytoid
dendritic cells, rather than canonical dendritic cells and
macrophages, can significantly impair type I interferon
signalling at 24 h post Plasmodium yoelii infection [136].
The ubiquitous STING-cGAS pathway has been shown
to enhance type I interferon production, and also po-
tently induces SOCS1 to inhibit the MyD88 / IRF7-
dependent type I interferon production which specific-
ally acts on pDCs to protect against early malaria infec-
tion. The loss of STING and cGAS in mice augments
the immediate type I interferon response from pDCs fol-
lowing malaria infection, and therefore protects the ani-
mal against early mortality [136]. Therefore, STING’s
activity and its crosstalk with other proinflammatory
pathways may be variable in complex diseases such as
malaria, and thus the manipulation of STING signalling
axis for therapeutic benefits may be difficult to achieve.
Viral evasion of STING
It is evident that many viruses can evade STING signal-
ling to establish a biological niche in mammalian cells,
and that those within the same family tend to adopt
similar evasive strategies [11, 62, 63, 65, 67, 68, 137–
148] (Table 3). For instance, several members of the
Gammaherpesviridae family were found to express
ORF52 protein homologs to disrupt cGAS activities, pre-
venting subsequent production of 2′-3′ cGAMP [48].
Species of the Flaviviridae and Coronaviviridae families
tend to secrete proteases that directly cleave or block
STING [140]; typical examples include the NS2B/3 and
NS4B proteases released by flaviviridae Dengue virus
and hepatitis C virus, respectively, which can both de-
grade hSTING. In particular, NS4B protease shows
strong homology to the ER-embedded N-terminal do-
mains of STING, leading to colocalisation and direct
protein-protein interactions with STING [11]. It has also
been suggested that tumour associated viruses such as
human papillomavirus and adenovirus could potentially
release oncogenic proteins to block cGAS/STING in-
teractions with tumour suppressors, hence comprom-
ising innate immunity and supporting cancer
progression [142].
The impairment or absence of interferon responses
often seen in HIV infection has been proposed as one of
the mechanisms by which this virus is capable of sup-
pressing host immunity [148–151]. Recent research sug-
gests that HIV-1 enhances the action of NLRX1 to
dampen STING activity [67] and recruits host 3′ exo-
nuclease TREX1 to degrade excessively produced,
reverse-transcribed, viral DNA thereby avoiding detec-
tion by the cGAS/STING pathway [68, 152]. The capsid
of HIV also regulates its association with host protein
cyclin A, which controls the masking of viral cDNA
from cGAS recognition in the cytoplasm and its expos-
ure in the nucleus to facilitate genome integration [146].
Mutations in the HIV-1 capsid sequence enhance its
binding to cyclin A prematurely in the cytoplasm enab-
ling DC sensing of double-stranded DNA and a potent
innate immune response against viral infection [146].
STING related autoimmunity
Type I interferons are key cytokines induced by antimicro-
bial and antiviral immunity. This family of cytokines con-
sists of the predominantly produced interferon-α and
interferon-β, and the less abundantly expressed subtypes
such as IFN-ε, −κ, −τ, and –ζ [153]. Type I interferons are
ubiquitously expressed by a variety of cells including mac-
rophages, lymphocytes, dendritic cells, fibroblasts and
haematopoietic plasmacytoid dendric cells, with a wide-
spread role in cellular biology [153, 154].
“Basal” expression of type I interferons is regulated via
an autocrine mechanism [155], whereas the activation of
interferon-inducing regulators such as STING can sig-
nificantly boost their expression by activating the tran-
scription factor IRF3. Type I interferons are released
extracellularly for detection by self or nearby interferon
receptors, IFNαRs, which are coupled to JAK1 (Janus
kinase 1) and TyK2 (tyrosine kinase 2) [86, 87]. This ac-
tivation further promotes the formation of STAT1-
STAT2 heterodimers [23, 89, 90] and the subsequent re-
cruitment of IRF9 to assemble the transcription complex
ISGF3 to upregulates the expression of a series of
interferon-stimulated genes (ISGs) [154]. A broad range
of ISGs have been found to control chemotaxis, cell mi-
gration, apoptosis, cell proliferation, and to regulate im-
mune detection and defense against infection; many of
which have been thoroughly reviewed previously [156–
160] (Table 4). Thus, dysregulation of type I interferon
signalling can cause an excessive production of ISGs, in
turn over-activating the immune system.
The persistent or excessive presence of cytoplasmic
DNA is one of the major causes for chronic inflam-
mation and autoimmune diseases. Chronic production
of type I interferons, termed “type I interferonopathy”,
is a key indication of immune dysregulation predom-
inantly associated with DNA-induced autoimmunity.
The overactive IFN-I response alerts cytotoxic im-
mune cells systemically via ISG production. This in
turn promotes sustained release of proinflammatory
cytokines including IL-1α/β, IL-12, and TNF-α, caus-
ing excessive inflammation and tissue damage [161–
163]. Autoimmunity also induces aberrant cell death,
which releases cellular components to T and B lym-
phocytes and leads to the production of self-reacting anti-
bodies that congest in capillaries [164]. Unresolved B cell
activation predisposes individuals to the development of
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systemic lupus erythematosus (SLE) that is clinically chal-
lenging to treat [152, 165, 166].
Systemic lupus erythematosus is a systemic chronic
autoimmune disease. [152, 165, 166] (Figure 5). SLE is
often diagnosed by the accumulation of serological anti-
nuclear antibodies (ANA) against nucleic acids released
from dead cells, which cause multiple tissue and organ
damage [167]. Chronic activation of DNA and RNA
sensing pathways triggered by infection and cell death
can contribute to the type I interferonopathy that predis-
poses individuals to SLE [166]. Mutations in nucleic acid
sensors (such as endosomal Toll-like receptors [168],
RIG-I [169], and DAI [170]), interferon regulatory fac-
tors [171] and DNases [172, 173] can also increase SLE
susceptibility. Recently, Ding and colleagues proposed
that the cGAS-STING axis could be another pathway
potentially exacerbating SLE, via the upregulation of
type I interferon production downstream of cytoplasmic
DNA sensing cascades [174]. However, STING defi-
ciency in macrophages in fact renders hyper-
responsiveness to endosomal TLR ligands, and STING
knockout mice have shown accelerated lymphocyte ac-
cumulation and expansion of an IFN-α -responding cell
population [175]. This therefore suggests inhibitory roles
for STING in SLE development. Sharma et al. also
Table 4 Summary of interferon-stimulated genes (ISGs)
Apoptosis Immune
Modultion
Cell Attraction &
Adhesion
Antiviral & Pathogen
Detection
CASP4
CASP8
BAK1
Fas/
CD95
PLSCR1
XAF-1
DAP
kinase
RID
MxA
MxB
ICAM1
SELL
CD47
ALCAM
IRF1–5 & 7
LGALS3B
IFN-γ
IL-12
TNF-α
SOCS
USP18
VEGF
FGF
VRP
PDGFRL
ECGF1
EREG
CTGF
MHC I&II
OAS1
Protein Kinase R
Viperin
Tetherin
IFI6
IFITM2
IFITM3
IRF1
IRF7
MHC I&II
Ribonuclease L
GTPase Mx1
ISG15
ISG20
ADAR1
APOBEC
Expression of ISGs are induced by type I interferon via the JAK-STAT signalling
pathway. ISGs are involved in a wide spectrum of cellular activities including
apoptosis, immune modulation, cell migration and adhesion, and antiviral re-
sponses. Some ISGs have multiple roles in immune regulation but are not re-
peatedly indicated in the table
Fig. 5 Cells and cytokines involved in STING-associated autoimmune diseases. Unresolved accumulation of cytoplasmic DNA can potentially trig-
ger chronic inflammatory responses which result in autoimmune diseases, including a systemic lupus erythematosus (SLE) and b Aicardi-
Goutières Syndrome (AGS). Both diseases are strongly associated with persistently enhanced type I interferon upregulation named type I interfero-
nopathy and subsequent B and T lymphocyte activation that potentiates systemic tissue and organ damage. Though STING dysregulation has
been suggested to play an essential role in the development of these diseases, current treatment of SLE and AGS still relies heavily on anti-
inflammatory therapies and DNA resolving methods to ameliorate symptoms. Gain of function mutations of STING can cause two autoimmune
diseases named c STING-associated vasculopathy with on-set in infancy (SAVI) and d familial chilblain lupus (FCL). Both diseases show similar man-
ifestations to SLE and AGS and are much less responsive to STING ligands than other immune stimuli. Treatments for SAVI and FCL are limited
but JAK inhibitors have been shown to ameliorate symptoms in patients with these two diseases
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showed that STING suppression can restrict the expres-
sion of regulatory T cell activation factor IDO-1 and
TLR negative regulators such as A20, SOCS1 and
SOCS3, contributing to uncontrolled systemic inflamma-
tion [175]. Since this effect is not seen in cells lacking
IRF3, the transcription factor mediating most of DNA
sensing responses downstream of the STING-TBK1 axis,
it is possible that STING is immunosuppressive in in-
flammatory pathways independent of cytoplasmic DNA
recognition. Therefore, autoimmune therapies targeting
the STING pathway should be considered with caution
and an awareness of the resultant STING down-
regulation, which may have opposing effects in certain
diseases.
AGS (Aicardi-Goutières Syndrome) is another
genetically-based autoimmune disease, characterised by
DNA-triggered type I interferonopathy [176] (Figure 5).
Patients with AGS often carry mutations in DNA restric-
tion factors including the 3′ exonuclease TREX1 [177,
178], dNTP restriction factor SAMHD (SAM domain
and HD domain) [179, 180], RNase H2 (ribonuclease
H2) [181, 182], dsRNA sensor IFIH1 (IFN-induced heli-
case C domain containing protein 1) [183, 184], and the
dsRNA-specific adenosine deaminase ADAR1 [185].
These regulators maintain a balance between the pro-
duction and degradation of nucleic acids, providing in-
trinsic protection against immune activation due to
“self-recognition”. Mutations of DNA or RNA restricting
factors cause nucleic acids to accumulate in the cyto-
plasm leading to SLE and AGS. Recent studies show that
the type I interferonopathy associated with SLE and
AGS is potentially cGAS-STING dependent, and that
the aberrant IFN-I response can be suppressed by the
loss of DNA sensor or STING in cells or animals ex-
pressing mutated Trex1 or Samhd [180, 186].
Gain-of-function mutations in STING have been iden-
tified in infants who suffer from severe and chronic vas-
culopathy and pulmonary inflammation, a condition
known as STING-associated vasculopathy with onset in
infancy (SAVI) [39] (Figure 5). Mutations of STING
V147 L, N154S, V155 M, and V155R were found to dir-
ect it to an active conformation enhancing dimerisation
and inducing TBK1-IRF3 signalling (Table 2). This re-
sults in an excessive IFN-I response in fibroblasts, kera-
tinocytes and immune cells to attract and amass
proinflammatory cells and regulators in capillaries and
tissues, ultimately causing lesions in these regions. Sus-
tained IFN-I signals activate interferon receptors and
promote expression of interferon-stimulated genes via
JAK1-Tyk2 signalling and STAT1-STAT2 dimers. In
vitro experiments and pioneering clinical studies suggest
that JAK adaptor inhibition effectively dampens STING-
mediated IFN-I over-activity. For instance, the elevated
IFN-I levels in biopsy samples from SAVI patients can
be restored close to that of the normal controls with
treatment using the JAK inhibitor, tofacitinib [39]. Fur-
ther investigation is required to examine the potential
adverse effects of interferon suppression, which is likely
to increase host susceptibility to infection.
Gain-of-function mutations of STING (Table 2) have
also been linked to the autoimmune disease familial chil-
blain lupus (FCL) [105, 108], a rare hereditary form of SLE
commonly associated with cytoplasmic DNA accumula-
tion in monogenic mutations of exonucleases TREX1
[187, 188] or SAMHD [189] (Figure 5). A recent discovery
reports FLC in five members of a four-generation family
sharing the same TMEM173 (STING) variant that en-
codes a single polymorphism of G166E. Structural analysis
of mutated STING dimers reveals strong hydrogen attrac-
tions between E166 on one monomer and two threonine
residues on the associating monomer, hence leading to en-
hanced adaptor dimerization and constitutive IFN-I -acti-
vated signalling [105]. Although limited treatment data is
currently available for FCL, the authors showed that con-
tinuous administration of the JAK inhibitor tofacitinib can
markedly ameliorate type I interferonopathy and associ-
ated symptoms in two patients. A similar therapeutic
strategy was previously proposed by Liu and colleagues
for treatment of STING-associated vasculopathy with on-
set in infancy (SAVI) [39]. Therefore, this therapeutic ap-
proach, based on mechanistic data, could be adapted to
treat type I interferonopathy found in various diseases.
STING regulates lipid metabolism
A new insight into STING research was recently pro-
vided by York and colleagues who suggested that this
protein is a crucial element of cholesterol metabolism
[45]. Previous studies indicate that high cholesterol
levels in the plasma membrane correlate with viral loads
and host susceptibility to infections [190, 191]. Virus
and microbial infections have been shown to modulate
lipid metabolism in the plasma membrane to facilitate
infectivity. For instance, influenza virus encodes fusion
protein haemagglutinin that is specialised in manipulat-
ing membrane lipid to permit penetration into the cyto-
plasm, a central step to viral infectivity and survival
[192]. In addition, membrane lipids can also form signal-
ling microdomain named lipid rafts which are frequently
hijacked by HIV for attachment, signalling and budding
to further promote infection [193, 194]. The antiviral
type I interferon response reduces cholesterol availability
in membranes to prevent viral infection; however the
underlying mechanism remains largely unknown [195–
197]. York’s group recently identified that STING/TBK1
signalling is critical to the production of type I inter-
ferons to reprogram lipid biosynthesis in pathogenic in-
fection [45]. They demonstrated that the shift from lipid
biosynthesis to lipid uptake not only affects the plasma
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membrane but also ER membranes, a cue to activate
STING, bypassing the dsDNA sensing pathway. How-
ever, since STING is not the only adaptor for innate im-
munity against pathogenic DNA in the cytoplasm, it is
conceivable that additional DNA sensors may further
enhance STING actions to modulate cholesterol metab-
olism and promote antiviral processes. In light of the
membrane fusion theory that potentially mediates
STING activation [198], virus-host lipid regulation at the
plasma membrane offers a promising and novel future
research direction.
Therapeutic targeting of the STING pathway
Studies on STING regulatory pathways provide novel in-
sights into antiviral and anti-inflammatory therapies. Ac-
tivating STING-dependent pathways has been developed
therapeutically for antiviral and, more recently, anti-
tumour benefit. The predominant approach taken has
been to introduce STING ligand cyclic dinucleotides to
promote the IFN-I response, to combat infection or to
prevent tumour progression. In contrast, type I interfer-
onopathy associated with STING over-activity represents
another set of pathologies underlying autoimmunity.
Counteracting these disease processes requires potent
suppression of STING signalling; attenuation of the
interferon receptor adaptor JAK is used as a current tar-
get, whilst inhibiting immune cell activation may also
help ameliorate symptoms.
Anti-tumour immunotherapies
Certain types of cancer cells express molecular struc-
tures specifically recognised by CD8α + dendritic cells
(DCs), which subsequently interact with cytotoxic T cells
to induce cancer cell death. This event, known as T cell
priming, is a prerequisite for anti-tumour adaptive im-
munity relying on activation of CD8α + dendritic cells to
promote IFN-I signaling in immature T cells [199]. How-
ever, cancer cells also boost anti-inflammatory immune
cells and regulatory T cells (Treg) to restrict CD8α + DC
activity thereby attenuating the activation of tumour-
suppressive T cells [200, 201]. Therefore, a potent and
long-acting adjuvant that can promote CD8α + DC ac-
tivities is highly desirable to enhance T cell priming and
subsequent anti-tumour immunity.
It has been reported that the IFN-I response critical to
T cell priming during tumourigenesis is dependent on
the cGAS / STING pathway [42, 43]. Loss of STING in
dendritic cells abolishes antigen cross-presentation from
CD8α + DC to T cells, whereas neither MyD88 nor TRIF
knockouts can significantly affect DC IFN-I signalling,
suggesting that STING may be the only adaptor central
to this process [43]. In both immunogenic and
irradiation-induced tumour models, tumour-derived
DNA was engulfed and recognised by the universal
DNA sensor cGAS prior to STING activation [42, 43].
However, direct stimulation with STING ligands also en-
hanced DC production of type I interferons, suggesting
that STING-inducing therapies may offer potential as
anti-tumour adjuvants.
Preclinical studies published recently suggest that
DMXAA-derived cyclic dinucleotides have been success-
fully applied in established mouse models of malignant
tumours achieving sustained tumour regression [202]. In
malignant tumour B cells, STING also induces an ER
stress response through the IRE-1 / XBP-1 (X-Box bind-
ing protein 1) pathway [203]. In the presence of 3′-3′
cGAMP STING dimers are phosphorylated and aggre-
gate, rather than undergoing degradation. This conse-
quently enables prolonged STING signalling to induce
apoptosis of tumour cells. Similarly, Tang et al. showed
administration of 3′-3′ cGAMP induces rejection of
chronic lymphotic leukemia in mouse models [203]. An-
other promising vaccine candidate is the recently devel-
oped STINGVAX which combines granulocyte-
macrophage colony-stimulating factor (GM-CSF) and
formulated 2′-5′ – 3′-5′ linked cyclic dinucleotide
[204]. In various established in vivo tumour models,
STINGVAX has shown notable positive effects on den-
dritic cell activation and in promoting tumour-
infiltrating T cells. Interestingly, activated cytotoxic T
cells also upregulate the expression of PD-L1 (pro-
grammed death ligand 1), which enhances the thera-
peutic action of pro-apoptotic ligand PD-1 to promote
tumour cell death. Although these STING-based vac-
cines have recently been developed and have been tested
in mouse models, the synergistic effect of the combined
STING agonist and immune promoting therapy repre-
sents a novel strategy to combat tumours by reinforcing
both adaptive immunity and anti-tumour targets.
JAK inhibitors ameliorate STING mutated autoimmunity
Inhibition of STING signalling can be achieved by tar-
geting interferon receptors. As previously mentioned,
gain-of-function mutations in TMEM173 (the gene en-
coding STING) underlie type I interferonopathies that
manifest in the autoimmune diseases, SAVI [39] and
FCL [105]. Constitutive STING signalling was detected
in both of these diseases resulting in dysregulated IFN-I
signalling via interferon receptors and the adaptors JAK
and Tyk. This leads to the accumulation of activated
STAT1/2 dimers in the nucleus, promoting transcription
of interferon-stimulated genes. Both Liu and König’s
groups demonstrated that treatment with the JAK1/3 in-
hibitor tofacitinib in patient biopsy samples suppresses
STAT activation and restores the STING response to im-
mune stimuli similar to healthy control cells [39, 105]
(Figure 5).
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Following the work of Liu and colleagues, Fremond’s
group conducted an 18-month clinical investigation on
three patients expressing STING-mutations to assess the
efficacy of the JAK1/2 inhibitor ruxolitinib [205] (Figure
5), which was previously found to partially inhibit STAT
activation in in vitro studies of STING mutants [39].
Marked amelioration of systemic inflammation and reduc-
tion of interferon-stimulated gene expression was consist-
ently observed in all three patients and in the subsequently
recruited additional four patients with STING gain-of-
function mutations. However, suspension of JAK inhibition
in one patient resulted in a dramatic inflammatory relapse,
though rescued by re-introducing ruxolitinib, demonstrat-
ing that this approach may be unsustainable and requires
continuous monitoring [105, 205, 206]. Nonetheless, it is
arguable that the partial inhibition of JAK-STAT pathway
has the advantage of preserving STING-dependent im-
mune protection against infection in these patients, since
no excessive infection incidents were observed during
these clinical trials [205]. Thus, it is timely to determine
whether such JAK inhibitors can be modified and adapted
for future treatment of type I interferonopathy.
Anti-inflammatory biologics
Anti-inflammatory biologics represent a further oppor-
tunity to suppress interferon responses in order to con-
trol type I interferonopathy in autoimmune diseases,
including but not limited to SLE, a major manifestation
linked to STING over-activity. For instance, the anti-
IFN-α drug sifalimumab is effective in controlling cuta-
neous and joint pain in SLE patients [207] (Figure 5).
Another approach to control SLE in STING gain-of-
function mutations is to deplete or inhibit B-cell re-
sponses to prevent the over-production of auto-
antibodies. The effective anti-SLE biologics, belimumab,
targets the BLyS protein of B lymphocytes, preventing B
cell activation and expansion critical to the production
of autoantibodies and downstream activation of T lym-
phocytes [208, 209] (Figure 5). A series of stage II and
stage III clinical trials have shown effective B-cell inhib-
ition and significant improvement of clinical symptoms
in combination with traditional care therapy of SLE in
the treatment group compared to placebo control, whilst
drug tolerance and immunosuppression-induced infec-
tion susceptibility were not markedly increased [209–
211]. This suggests an effective drug efficacy and safety
of belimumab over another B-cell depleting drug rituxi-
mab, which failed to ameliorate SLE symptoms in phase
II and III trails [212]. Unlike JAK inhibitors and anti-
IFN biologics, B-cell targeted therapies are much less ef-
fective in controling type I interferonopathy that conse-
quently cause complex inflammatory responses in
STING mutant patients. However, they are still com-
monly used to treat the SLE-related consequences of
STING over-activation to stall symptom deterioration,
while they have also been considered suitable adjuvant
candidates for STING-targeted therapeutics.
Delivery of STING ligands
Accumulating evidence link STING-mediated IFN-I sig-
naling to anti-tumour activity, and thus STING ligands
have been proposed to offer promising immune-
enhancing therapies to defend against DNA infections
and tumourigenesis [41, 213]. However, targeting intra-
cellular proteins such as STING remains challenging as
the plasma membrane is a highly hydrophobic and size-
selective barrier that resists passive entry of chemicals
[57]. In contrast to the de novo STING ligand 2′-3′
cGAMP [48], other cyclic dinucleotides are produced
exogenously by pathogens and introduced into the cyto-
plasm by active transport or particle fusion [47, 50, 214].
Since the hydrophilic phosphate groups in dinucleotide
compounds are strongly repelled by membrane lipid bi-
layers, designing an effective delivery system for cyclic
dinucleotides would provide a significant step forward in
the development of STING-specific therapeutics.
Under in vitro studies, transfection of microbial cyclic
dinucleotides is aided by digitonin [35, 39, 50, 104] or
liposomal-based systems such as Lipofectamine® [47,
102] (Figure 6). The former method, first described by
Woodward’s group [35], aims to achieve reversible per-
meabilisation of cellular membranes to increase uptake
of chemicals [215–217], but is limited to in vitro studies
due to high toxicity in vivo. In contrast, the liposomal-
based delivery system is based upon the principle of en-
capsulating drugs in artificial double-layered liposomes
for cytoplasmic delivery via liposomal fusion. The system
is highly adapted for a variety chemicals and has been
used in both laboratory studies and clinical practice
[218].
In light of the liposome-based designs, Miyabe’s group
has reported that the YSK05-based lipid particles were
able to entrap and deliver cyclic di-GMP into the RAW
264.7 macrophage cell line [219] (Figure 6). These parti-
cles induced cellular expression of type I interferon
genes which were effectively blocked by the TBK1 in-
hibitor BX795, suggesting that the interferon response
was specifically induced via the STING/TBK1 pathway.
Furthermore, the YSK05-based particles also express
high levels of the antigen-presenting molecule MHC
class I and T cell co-stimulating molecules CD80 and
CD86 that are a prerequisite of T lymphocyte activation;
all of these characteristics suggest they offer potential as
adjuvants in anti-tumour therapies. Preliminary tests
carried out by Miyabe and colleagues showed that mice
immunized with cyclic di-GMP containing YSK05-
liposomes reject tumour implantation compared to
matched controls [219]. Subsequently, Nakamura’s group
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demonstrated that in vivo injection of these particles
greatly enhances the expression of IFN-I and MHC class
I molecules in tumourigenic mice, resulting in aug-
mented NK cell activation and potent innate immune
protection against lung melanoma metastasis [220].
Therefore, the YSK05 liposomes offer a potential vehicle
to assist delivery of STING ligands and to develop
STING-based adjuvants for cancer immunotherapy.
As an alternative approach, a nanoparticle-based delivery
system developed by Lee and colleagues also enables
in vitro delivery of cyclic dinucleotides to target STING
pathways for anti-tumour effects [221] (Figure 6). This
method employs polyethyleneimine / hyaluronic acid (LH)
-based hydrogels to enclose dinucleotide drugs into micron
size spheres, which are selectively taken up by phagocytic
cells such as RAW 264.7 macrophages, L929 fibroblasts
and bone marrow-derived macrophages (BMDMs), but not
by non-phagocytic fibroblasts. Thus, the micron-sized par-
ticles appear to target phagocytosis specifically to gain entry
into the cytoplasm. Furthermore, Lee et al. showed that
LH-cGAMP hydrogel can induce IFN-I spikes in
RAW264.7 macrophages, which were more than twice the
magnitude of that induced by lipofectamine-delivered
cGAMP at the same dose [221]. Administration of
ovalbumin-containing LH-cGAMP particles in mice acti-
vates both the type I interferon response and humoral pro-
duction of IgG to protect against ovalbumin challenge.
Taken together, Miyabe and Lee’s work indicates that the
modified liposome-based delivery systems can markedly en-
hance in vitro and in vivo delivery of cyclic dinucleotide to
cytoplasmic STING, and this success will promote the de-
velopment of novel cancer vaccination and immunother-
apies dependent on STING signalling.
Conclusions
Cytoplasmic DNA has been implicated in many human
pathologies, many associated with chronic inflammation.
Research has revealed that the ER transmembrane protein
STING is a crucial player in dsDNA pathogen -sensing
pathways whose dysregulation contributes to the develop-
ment of several diseases. By responding to DNA sensors
and cyclic dinucleotides, STING induces IRF3- and NF-κB
–dependent pathways to elicit proinflammatory responses
against infection and cancer progression. STING also dir-
ectly crosstalks with several other regulators to modulate
critical biological processes including autophagy and
Fig. 6 In vitro and in vivo delivery of STING agonists. The plasma membrane is a selectively permeable barrier that prevents cytoplasmic entry of
large or hydrophilic molecules, including naked cyclic dinucleotides (CDNs) (1). In vitro (blue background) delivery of dinucleotide compounds
could be achieved by the liposomal delivery system (2), or via reversible permeabilisation of plasma membrane to allow diffusion of naked CDNs
into the cytoplasm (3). Recently designed YSK05-containing liposomes (4) could carry c-di-GMP across plasma membranes to induce DDX41-
mediated STING activation as well as enhance the expression of MHC class I molecules and T cell co-stimulatory receptors (not demonstrated),
and thus it is considered to be a potential adjuvant for cancer immunotherapy. In addition, the polyethyleneimine/ hyaluronic acid (LH) hydrogel-based
vesicles use phagocytosis to deliver both STING ligands and antibody-stimulating agents such as ovalbumin (dark triangles) to cells (5), and enhance both
STING-dependent innate immunity and MHC class II-activated adaptive immunity to suppress cancer growth. Both YSK05 particles and LH hydrogel-based
particles have been tested in vivo (green background) to stall tumour progression in mice (6)
Li et al. Journal of Inflammation  (2017) 14:11 Page 15 of 21
cholesterol biosynthesis. It is evident that activating STING
results in the type I interferon response to protect against
infection and tumour formation, while dysregulated gain-
of-function STING mutations lead to detrimental conse-
quences of autoimmunity. Understanding the molecular
signalling mechanisms of STING activation has provided
new insights to advance therapeutic strategies in treating
infection, cancer and autoimmune diseases. It has also
prompted the development of intracellular delivery systems
to administer STING agonists. Despite the fact that STING
has only been studied for a decade, this adaptor protein will
continue to attract attention in immunology research and
clinical practice into the future.
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